Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
May 14, 2020 at 05:05 pm EDT
Share
Skinvisible, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was USD 43,166 compared to USD 69,347 a year ago. Operating loss was USD 539,777 compared to USD 597,935 a year ago. Net loss was USD 1.702 million compared to net income of USD 158,342 a year ago. Basic loss per share from continuing operations was USD 0.57 compared to basic earnings per share from continuing operations of USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.57 compared to diluted earnings per share from continuing operations of USD 0.01 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
